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Immunologic hypersensitivity to collagen, the major structural component of 
connective tissue, could explain both the systemic nature and chronicity of the 
inflammation occurring in rheumatoid arthritis. Recent demonstrations of anti- 
bodies to collagen in sera from patients with rheumatoid arthritis support this 
premise (1-8). Also consistent with this hypothesis is the distribution of collagen 
in structurally distinct types in various tissues.  For example, types I and HI 
collagens are found in the skin and parenchyma  of several organs, whereas type 
II exists in cartilage (9). Thus,  an immune response to the cartilage type of 
collagen  (type II)  could  explain  the  predilection of rheumatoid arthritis  to 
involve diarthrodial joints. 
Native collagens consist of three polypeptide chains linked in triple helices. 
Terminal peptides (telopeptides) do not have a helical structure and are more 
variable in amino acid content (10). Type I  collagen combines two  al-type I 
chains with one a2-chain and is depicted as [al(I)]2a2. Types II and III collagens 
are comprised of three al-type II chains and three al-type HI chains, respec- 
tively. Thus, type II is depicted as [al(II)]3 and type III as [al(III)]3. 
Injection of heterologous type I and II collagen in complete Freund's adjuvant 
has been reported to elicit type-specific antibody responses in rats (11) and mice 
(12). This paper reports that approximately 40% of rats injected intradermally 
with native type H collagen, derived from human, chick, or rat cartilage, in 
either complete or  incomplete Freund's  adjuvant,  develop an  inflammatory 
arthritis.  In contrast, type I  and III collagen are not arthritogenic. This new 
animal model suggests that immune responses to type II collagen could play a 
role in inciting or perpetuating joint inflammation in other arthritides. 
Materials and Methods 
Rats.  Outbred female Wistar, Sprague-Dawley and inbred Wistar-Lewis rats were obtained 
from Microbiological Associates  (Bethesda,  Md.),  Harlan  (Indianapolis,  Ind.) or Charles River 
Breeding Laboratory (Wilmington, Mass.). These rats were housed in metal cages and given water 
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and standard rat chow ad lib. They weighed 150-225 g  and were 10-24 wk of age at the time of 
immunization. 
Tissues.  The  xiphoid  cartilage  of 3  wk  old  White  Leghorn  chicks,  rendered  lathyritic  by 
administration of ~-aminopropionitrile fumarate (BAPN, ~ Sigma Chemical Co.,  St.  Louis, Mo.) 
(13),  was used as the source of chick type II collagen. Similarly, weanling outbred female Wistar 
rats were given BAPN (0.4%) in water for 3 wk, and their xiphoid and hip cartilage was used after 
careful dissection to avoid contamination by bone. Human collagens were prepared from neonatal 
skin and cartilage obtained at autopsy. Skin and cartilage were pulverized in liquid nitrogen with 
a freezer mill (Spex Industries, Inc., Metuchen, N.J.). All subsequent procedures were performed 
at 4°C. 
Skin Collagens.  Type I collagen was extracted from skin powder by overnight suspension with 
gentle shaking in 5 vol of 0.05 M Tris/1 M NaC1, pH 7.4. After centrifugation (20 min at 20,000g), 
collagen in the supernate was precipitated by gradual addition of NaCl to a final concentration of 3 
M. The precipitate was redissolved in 0.05 M Tris/1 M NaC1 and again precipitated in an identical 
manner. After redissolving in the neutral salt buffer, the collagen was precipitated by the addition 
of 0.1 vol of i  M  acetic acid. The precipitate was collected and dissolved with 0.5 M  acetic acid, 
reprecipitated  with NaC1  to  a  final concentration of 1  M,  redissolved with  0.5  M  acetic acid, 
dialyzed exhaustively against 0.1 M  acetic acid, and lyophilized. 
Additional type I collagen was obtained from the skin pellet after neutral salt extraction by 
suspending the pellet in 5 vol of 0.5 M acetic acid for 24 h. After an identical subsequent extraction, 
collagen in both supernatos was precipitated by the addition of NaCl to a  final concentration of 1 
M,  redissolved  in  0.5  M  acetic  acid,  precipitated  again  with  NaC1,  dissolved  in  acetic  acid, 
dialyzed, and lyophilized. Pepsin-solubilized type I collagen and type III collagen were prepared 
from the skin residues by methods previously described (14). 
Cartilage  Collagens.  Pepsin-solubilized type II collagen was prepared by washing the carti- 
lage powder with 20 vol of 0.05 M Tris/2 M MgC12, pH 7.4, at 4°C. The extract was stored at -20°C 
for subsequent use as a crude protooglycan complex. The residue was washed twice with distilled 
water, then suspended in 0.5 M acetic acid, and the pH of the suspension was adjusted to 2.5 by the 
addition of formic acid. Pepsin (two times crystallized, Worthington Biochemical Corp., Freehold, 
N.J.) was then added (1/50 g wet weight), and digestion was allowed to proceed for 72 h at 4°C with 
gentle shaking. The undigested residue was separated by centrifugation (20,000 g  for 20 min) and 
extracted two more times with pepsin under identical conditions. The supernates from the three 
extractions were dialyzed against 0.05 M Tris/0.2 M NaC1, pH 7.6, diluted 10-fold with the buffer 
and passed through a  column of fresh DEAE cellulose (DE 52, Whatman Chemicals, Div. W & R 
Balston, Maidstone, Kent,  England) that had been equilibrated with the same buffer. Collagen 
was eluted with the buffer and precipitated by the addition of NaC1 to make a final concentration 
of 3 M. The precipitate was dissolved in 0.5 M acetic acid, dialyzed against 0.01 M Na~HPO4, and 
the collagen precipitate was harvested by centrifugation. After resolubilization in acetic acid and 
precipitation with 1 M NaC1, it was redissolved in acetic acid, dialyzed against 0.1 M acetic acid, 
and lyophilized. 
Soluble type II tropocollagen was obtained from the cartilage of lathyritic chicks or rats. After 
pulverization, the powder was extracted with a 0.4 ionic strength phosphate buffer, pH 7.6, for 24 
h.  After an additional extraction,  the two supernatos were dialyzed against 0.05 M  Tris/0.2  M 
NaCl,  pH  7.6,  passed  through  DEAE,  and  purified in  a  manner described  above  for pepsin- 
extracted collagen. 
c~-Chains.  The constituent s-chains of human or chick type II collagen were prepared by ion 
exchange chromatography on columns of carboxymethyl-cellulose (CM-cellulose,  CM-52,  What- 
man, Inc., Clifton, N.J.) as previously described (14). 
Collagen Analysis.  The  purity  of each collagen  preparation was  assessed  by  CM-cellulose 
chromatography and amino acid analysis by using an automatic analyzer (Beckman Instruments, 
Inc., Spinco Div., Palo Alto, Calif., model 121) as previously described (14). 
Uronic acid assay (15) indicated that proteoglycan contamination of the collagen samples (1 mg/ 
ml 0.1 M acetic acid) was less than the 5 pg/ml minimum detectable by the assay. 
Adjuvants.  The  complete  Freund's  adjuvant  (CFA)  used  for  all  collagen  immunizations 
1Abbreviations  used  in  this paper:  BAPN,  ~-aminopropionitrile  fumarate;  CFA,  complete 
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(Difco,  code 0638,  Difco Laboratories,  Detroit,  Mich.) contained Mycobacterium  butyricum  at a 
concentration of 0.5 mg/ml. This preparation failed to induce adjuvant arthritis (16) in 30 Wistar 
rats when 0.5 ml was emulsified with 0.5 ml 0.1 M acetic acid and injected intradermally on the 
back. 
As a  control for the collagen-induced arthritis, adjuvant arthritis was induced by intradermal 
injection of 0.1  ml complete  Freund's adjuvant H37Ra  (CFA  H37).  This preparation contained 
desiccated, heat-killed M. tuberculosis  H37 Ra (Difco Laboratories, code 3114) at a concentration of 
10 mg/ml in incomplete Freund's adjuvant (ICFA, Difco Laboratories, code 0639). 
Sensitization Procedures.  Collagen was dissolved in 0.1 M  acetic acid at a  concentration of 1 
mg/ml. Equal volumes of collagen solution and CFA or ICFA were mixed, and a stable emulsion 
was  made  with  an  emulsifier  (VirTis  45,  VirTis  Co.,  Inc.,  Gardiner,  N.Y.).  1  ml  of the cold 
emulsion was then immediately injected intradermally in four to six sites on the backs of the rats 
(11). Small ulcers frequently formed at the injection site, but these healed without sequelae in 7-10 
days. Control injections consisted of the acetic acid emulsified in CFA or ICFA or human or chick 
type  II  collagen  dissolved in  acetic  acid  but  injected intradermally without  adjuvant.  As  an 
additional control, 1.0 ml of MgC12-extractable cartilage proteoglycans containing approximately 
100  /~g uronate per ml was mixed with 0.5 ml of CFA or ICFA,  emulsified,  and injected in a 
manner identical to the collagens. Unless otherwise specified, booster doses consisting of 0.5 mg 
collagen dissolved in 0.5 ml 0.1 M acetic acid were given intraperitoneally (i.p.) without adjuvant 
21 days after  primary immunization, i ml of  the MgCI~ extract  was given i.p.  after  an identical 
interval  to the proteoglycan control animals. Adjuvant arthritis  was induced by intradermal 
injection  of  0.1 ml CFA H37 at  the base of  the tail. 
Arthritis  Evaluation.  Animals were observed  daily  for  the  onset  of  arthritis,  and an arthritic 
index was derived by grading the severity  of  involvement of  each paw from 0 to 4. Scoring was 
based on the degree of  periarticular  erythema and edema as well as deformity of  the  joints,  as 
previously  described  (16).  Swelling  of  hindpaws was also  quantitated by measuring  the  thickness 
of  the ankle from medial to lateral  malleolus with a constant tension caliper  (B.C.  Ames Co., 
Waltham, Mass.). Results could be reproducibly  expressed to the nearest 0.1 ram. 
Histopathology.  Animals were sacrificed,  and involved paws were amputated on the day of 
onset  of  arthritis  or  at  later  periods  ranging  up  to  6  mo after  onset.  After  immersion  in  10%  neutral 
formalin,  the  joints  were  decalcified,  imbedded  in  paraffin,  sectioned,  and  stained  with  hematoxy- 
lin  and eosin. 
Joint Roentgenography.  Sequential joint  roentgenograms were made on dental X-ray film 
(Kodak DF45, Eastman Kodak Co.,  Rochester, N.Y.) 
Bacteriology.  Blood was obtained  aseptically  by cardiac  puncture  from eight  rats  within  24 h 
of  the onset  of  arthritis  and inoculated  onto sheep  blood agar  plates.  Inflammed synovia  obtained 
from  five  rats  at  the onset  of  arthritis  were  similarly  inoculated  onto identical  nutrient  media  and 
observed  for  72 h. Finally,  paired sera  and synovia  from an additional  four  rats  were collected  on 
the day  of  onset  of  arthritis  and  cultured  for  Mycoplasma arthritidis  by Microbiological  Associates 
(Bethesda, Md.). 
Results 
Incidence and Specificity of Collagen-Induced Arthritis.  A  chronic inflam- 
matory arthritis developed in 144 of 348 rats (41%) injected intradermally on the 
back with type II collagen derived from human, chick, or rat cartilage and either 
CFA or ICFA.  These data are summarized  in Table I.  The arthritis  could be 
induced  with  approximately  equal  frequency  in  outbred  female  Wistar, 
Sprague-Dawley or  inbred  Wistar-Lewis  strains  whether  CFA or ICFA  was 
employed. In contrast, type I collagen derived from human, chick, or rat skin or 
type III collagen derived from human skin were not arthritogenic  in a  total of 
181 rats. In the other control groups, type II collagen without adjuvant, MgCl2- 
extractable cartilage proteoglycans, denatured  al(II) chains,  and the type and 
dose of CFA or ICFA injected without collagen also did not cause arthritis in a 
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TABLE  I 
Preparations  which Induced Arthritis 
Adjuvant 
Preparation injected  Rat strain  Total 
CFA*  ICFA* 
% 
Human type II$  Wistar  43/78  14/47  46 
Chick type II  Wistar  4/10  15/33  44 
Chick type II  Wistar-Lewis  24/60  40 
Rat type II$  Wistar  6/20  17/50  33 
Chick type II  Sprague-Dawley  5/10  50 
CFA H37  Wistar  40§ 
* Number of rats developing arthritis/number of rats injected with the preparation in the 
specified adjuvant.  There  was  no  significant difference in  the  incidence of arthritis 
induced by heterologous or homologous type II collagens by Chi square analysis. 
Pepsin-modified. 
§ Incidence (16/40) of adjuvant-induced arthritis, produced by intradermal injection of 0.1 
ml adjuvant oil containing M. tuberculosis  H37Ra  (10 mg/ml). 
TABLE  II 
Preparations which Did Not Cause Arthritis 
No. of rats injected 
Preparation injected  Adjuvant 
CFA  ICFA 
Total 
Human type I*  45  10  55 
Human type I  10  10  20 
Chick type I  20  25  45 
Rat type I  10  10  20 
Human type III*  31  10  41 
Human al(II) chains*  20  10  30 
Chick al(II) chains  10  10  20 
Human cartilage proteoglycans  10  10  20 
Human type II* without adjuvant  20 
Chick type II without adjuvant  10 
Acetic acid~  30  10  40 
* Pepsin-modified. 
* 0.5 ml 0.1 M acetic acid. 
Onset and Course of Arthritis.  The clinical features of the collagen-induced 
arthritis were similar whether  heterologous or homologous type II collagen was 
the immunogen  or whether  CFA or ICFA  was used. The onset of arthritis  was 
explosive occurring 14-60 days postimmunization  with a  peak  onset at 20 days 
and a  median onset at 21 days for a  group of 61 rats examined daily. Typically, a 
hindlimb  became severely red and edematous  within a  16-24-h period such that 
the arthritic index was 5,0  _+ 0.4 (mean  _  SEM) for a  group of 28 rats evaluated 
on the day of onset of arthritis.  10 had bilateral hindlimb involvement  (Fig. 1), 
whereas  in  18 the disease remained  unilateral. 
The  hindlimb  swelling  could  also  be  easily  quantified  by  measuring  the FIG. 1.  Comparison  of normal rat hindlimbs (A) with those (B) rendered arthritic  by 
intradermal injection  of  human type  II  collagen  in  ICFA, Both arthritic  paws were graded 
as  4 by  the arthritic  index and had an intermalleolar  thickness of  greater than 10  mrn by 
constant tension caliper  measurement. Ankle thickness of  age-matched normal rats was 
consistently  less  than 7 ram. 
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thickness of the ankle between the malleolae with a constant tension caliper. 
The mean ankle thickness was 10.2 _+ 0.3 mm for 10 arthritic joints evaluated on 
the  day of onset of arthritis  induced in  Wistar-Lewis rats  by chick type II 
collagen in  ICFA  compared to  6.4  _+  0.1  for  20  ankles  from  age-matched, 
uninjected female Wistar-Lewis rats. 
No additional limbs became affected after the initial 48 h of disease. Forepaw 
inflammation occurred in 10% of the entire arthritic population. Involvement 
was predominately distal with ankle, tarsal,  and interphalangeal inflamma- 
tion. Peak severity occurred within 4 days after the onset with each involved 
limb usually reaching a maximum score by the arthritic index. Weight bearing 
on the affected limb was poorly tolerated by the rats,  and swelling usually 
persisted 5-8 wk, gradually culminating in a deformed joint. Nine rats had an 
identical clinical course but a delayed onset 30-60 days after primary immuniza- 
tion. All had received i.p. booster injections at 21 days. 
Spontaneous exacerbations of  disease did not occur; however, i.p. booster doses, 
identical to those given at 21 days, as long as 6 mo after original immunization 
caused a  recrudescence within 3 days in all 11 previously arthritic rats when 
rechallenged. None of 20 rats which initially remained nonarthritic after injec- 
tion of type II collagen became arthritic when rechallenged aiter similar time 
intervals. 
Mild hair and weight loss but no ocular inflammation, hematuria, or mucosal 
lesions occurred in the arthritic rats. No rat died during active joint inflamma- 
tion. 
Comparison with Adjuvant Arthritis.  The clinical features of the type II 
collagen-induced arthritis were similar to those of adjuvant-induced disease. A 
single injection of  human type II collagen in CFA or ICFA in another group of 62 
Wistar rats caused arthritis in 33 (53%), whereas adjuvant arthritis developed in 
16 of 40 Wistar rats (40%) injected with CFA H37. Likewise, the onset of clinical 
disease was similar (mean day of onset 17.0 _+ 0,6 for 28 collagen-induced  disease 
rats vs.  15.6 _+ 0.4 for 16 adjuvant arthritis rats) as were their mean arthritic 
indices studied within 48 h of onset (mean 5.0 _+ 0.4 for 26 collagen arthritis rats 
vs. 3.9 _+ 0.4 for 16 adjuvant arthritis rats). 
Pathology.  Groups of six Wistar-Lewis rats were sacrificed before the onset 
of arthritis on each of  days 11-14 after injection of chick type II collagen in ICFA, 
and their spleen and inguinal and cervical lymph nodes were examined grossly. 
Marked progressive hypertrophy of these tissues occurred during this period, 
which immediately  preceded  the usual time of  onset of arthritis. Histopathologic 
sections of  diarthrodial  joints showed that injection of  type II collagen with ICFA 
produced a chronic proliferative synovitis which secondarily destroyed articular 
cartilage and bone.  Synovium obtained within 24 h  of the onset of arthritis 
showed marked edema and infiltration by dense aggregates ofmononuclear  cells 
and occasional neutrophils. There was no vessel wall necrosis. Serial sections of 
joints examined at later stages of inflammation showed proliferation of synovio- 
cytes and fibroblasts resulting in synovial hypertrophy and fibrosis. This syn- 
ovial  pannus,  in  turn,  eroded the  cartilage and  subchondral bone  (Fig.  2). 
Periosteal new bone formation was prominent and uniformly  culminated in joint 
ankylosis. Numerous mononuclear cells persisted in the synovium for longer 
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FIG.  2.  Section of ankle joint taken approximately 2 wk after onset of type II collagen- 
induced arthritis.  Synovial proliferation and intense infiltration by mononuclear cells is 
producing cartilage and bone erosion. Hematoxylin and eosin x  200. 
and sections of the trachea showed no evidence of generalized cartilage inflam- 
mation. Likewise, histologic examinations of the skin, lung, and kidney were 
normal. 
Roentgenography.  Roentgenographs mirrored the progression from soft tis- 
sue swelling, articular bone erosions, and prominent periosteal new bone forma- 
tion,  to  bony  ankylosis  in  the  carpal,  tarsal,  metacarpal,  metatarsal,  and 
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FIG.  3.  Comparison ofroentgenograph of normal rat hindpaw (A) with that (B) from a rat 
whose arthritis was induced by chick type II collagen in ICFA. Soft-tissue swelling, bone 
destruction  and  periosteal  new  bone  formation  are  prominent  2  wk  after  the  onset  of 
inflammation. 
Additional  Attempts  to  Induce  Arthritis.  Primary  and  booster  injection 
regimens  employing 2.0 mg per rat  of chick type I  collagen,  human  type III 
collagen, or chick al(II) chains in CFA failed to induce arthritis in a total of 50 
additional rats. Also human type I tropocollagen which had been passed through 
DEAE in a manner identical to the preparative technique for type II collagen did 
not  cause  arthritis  in  20 rats.  No  significant  differences  in  the  incidence  of 
arthritis were found with doses of  type II collagen ranging from 0.5 to 2.0 mg per 
rat. 
Cultures for Microorganisms.  No bacterial or mycoplasmal organisms were 
detected in blood or synovial cultures taken at the onset of disease. 
Discussion 
These  data  demonstrate  that  heterologous  or  homologous type  II  collagen 
derived from cartilage  when injected intradermally  on the back with CFA or 
ICFA  induces  arthritis  in  approximately  40%  of rats  of several  strains.  The 
structurally distinct types I and HI collagen derived from skin are not arthrito- 
genic.  Likewise,  the  denatured  constituent  a-chains  of type  II  do  not  cause 
disease.  Various infections such as M. arthritidis  (17) or Salmonella  (18) can 
cause arthritis  in rats.  However, an infectious agent or product contaminating 
our preparations is unlikely to explain our results for several reasons: cultures 
for microorganisms  were negative;  the identically prepared  collagen failed to 
induce arthritis when injected in the absence of adjuvant; multiple preparations 
of type II collagen from human,  chick or rat sources induced arthritis;  collagens 
prepared and  injected  in  two  geographically separate  laboratories  caused  arthri- 
tis  at  all  times  of  the  year;  the  latent  period after  injection  was longer  than  that 
usually observed after  inoculation with an infectious  agent (17);  further, the 
arthritis  had a lengthy course with no spontaneous exacerbations; and finally, 
the synovial infiltration  was mononuclear rather than neutrophilic,  even ini- 
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This  type II  collagen-induced arthritis  is  distinct from the  previously de- 
scribed adjuvant-induced arthritis of rats (16), since the disease can be produced 
after injection of type II collagen in oil not containing bacterial preparations. 
Indeed, the equivalent frequency of arthritis whether CFA or ICFA was em- 
ployed with the type II collagen is surprising. Possibly, type II collagen per se 
has an adjuvant capacity, but would still require oil since the protein injected 
alone was incapable of inducing arthritis. While the precise relationship of the 
collagen-induced arthritis to adjuvant-induced arthritis is at present uncertain, 
Steffen and Wick have reported delayed-type skin reactions to rat skin collagen 
in  adjuvant  arthritis  (19). Moreover,  we  have  found that  peripheral  blood 
mononuclear cells from rats with  adjuvant arthritis exhibit antigen-induced 
tritiated thymidine incorporation in vitro to homologous type I and II collagen 
(20). Hemagglutinating antibodies specific for these native collagens and their 
a-chains can also  be detected in  sera from rats  with  adjuvant arthritis  (D. 
Trentham and J.  David,  unpublished data).  Immunologic hypersensitivity to 
collagen may thus  be  a  common feature of adjuvant-  and  collagen-induced 
arthritis. 
The  moiety responsible  for the  arthritogenicity of our  cartilage  collagen 
preparations is uncertain, but at present we assume it to be type II collagen. By 
uronic  acid  assays  and  CM-cellulose  chromatography, our  type  II  collagen 
preparations are free from proteoglycan and type I collagen (13) contamination, 
respectively. A cartilage proteoglycan extract did not cause arthritis. Nonethe- 
less,  it is not possible at present to exclude a  small amount of proteoglycan 
linked to collagen being important in the induction of arthritis. The principle 
responsible for the induction of adjuvant arthritis is of interest in this regard. 
Initial investigation indicated that arthritogenic activity resided in the wax D 
fraction which is separated from mycobacteria by ultracentrifugation. Subfrac- 
tions of wax D containing peptidoglycolipids could also be chromatographically 
isolated which retained arthritogenic potential (16). Subsequent work suggests 
that adjuvanticity and arthritogenicity are properties of different glycopeptides 
contained in these subfractions (21). Finally, it has recently been proposed (22) 
that the common peptidoglycan backbone of bacterial cell walls explains the 
ability  of extracts  from  several  different bacteria to  induce arthritis  when 
emulsified in  adjuvant  oil.  Since  these  bacterial  peptidoglycans may have 
structural similarities to cartilage proteoglycans, the possible participation of 
these latter molecules in the induction of our arthritis must be further investi- 
gated before it can be firmly concluded that specific determinants on collagen 
are arthritogenic. 
Intact nonhelical telopeptide regions of the type II molecule are not required 
for arthritogenicity, since pepsin-modified type II collagens were as effective in 
causing arthritis as the tropocollagen molecules. Although it is difficult to be 
certain that the helical structure of collagen was maintained during the process 
of emulsification in oil before injection, the finding that al(II) chains did not 
induce arthritis makes this assumption reasonable. As recently demonstrated 
for myoglobin, the conformational integrity of immunogenic sites  on native 
proteins can be preserved during emulsification  in oil (23). Humoral and cellular 
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denatured al(II) chains,  presented in asubsequent paper, 2 further support the 
thesis that sensitization to the helical form of type II collagen was achieved. 
Two features of this animal model of arthritis are of particular interest. First, 
this represents the only experimental model in which disease can be regularly 
provoked with ICFA injected intradermally  with a  constituent of homologous 
tissue, suggesting that an autoimmune process may have been induced with oil 
not  containing  bacterial  preparations.  This  is  distinct  from  other  models  of 
experimentally-inducible  autoimmunity to organ-specific antigens,  which usu- 
ally require injection of CFA with tissue components (24) and demonstrates an 
unusual property attributable to the type II collagen protein. Second, histopath- 
ologic studies show that  the primary lesion provoked by type II collagen is a 
chronic proliferative synovitis.  Destruction of articular  cartilage and bone ap- 
pear  to be sequelae of synovial inflammation.  Mononuclear  cells invade  and 
persist in the synovium, suggesting that immune processes may be important in 
the pathogenesis of disease. These characteristics sufficiently resemble those of 
rheumatoid arthritis to suggest that this may be an appropriate animal model 
for the human disease. 
In conclusion, type II collagen from either heterologous or homologous sources 
has been found to be arthritogenic in rats. There is an apparent requirement for 
type-specific helical determinants in evoking the disease. This conclusion coin- 
cides with Hahn et al. (11) concerning the conformationally-dependent antigenic 
determinants responsible for the humoral specificity of type I and II collagen. By 
recently achieving passive transfer of this arthritis  by spleen and lymph node 
cells sensitized to type II collagen, a we have directly implicated immunologic 
hypersensitivity to collagen in the causation of this autoimmune disease. 
Summary 
We have found that intradermal  injection of native type II collagen extracted 
from human, chick or rat cartilage induces an inflammatory arthritis in approx- 
imately 40%  of rats of several strains  whether complete Freund's  adjuvant or 
incomplete Freund's adjuvant is used. Type I or III collagen extracted from skin, 
cartilage  proteoglycans and  al(II) chains were incapable of eliciting arthritis, 
as  was  type II  collagen  injected  without  adjuvant.  The  disease  is  a  chronic 
proliferative  synovitis,  resembling  adjuvant  arthritis  in rats  and  rheumatoid 
arthritis  in humans.  Native type II collagen modified by limited pepsin diges- 
tion still produces arthritis,  suggesting that type-specific determinants residing 
in the helical region of the molecule are responsible for the induction of disease. 
Since homologous type II collagen emulsified in oil without bacterial prepara- 
tions regularly causes the disease, this new animal model of arthritis represents 
a unique example of experimentally-inducible autoimmunity to a tissue compo- 
nent. 
2  Trentham,  D.  E.,  A.  S.  Townes, A.  H.  Kang, and J.  R.  David. Humoral and  cellular 
sensitivity to collagen in type II collagen-induced arthritis  in rats.  Manuscript submitted for 
publication. 
3 Trentham, D. E., R. A. Dynesius, and J. R. David. Passive transfer of type II collagen-induced 
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